CoRegen, Inc. Welcomes Dr. Sonal Gupta as Chief Medical Officer
CoRegen, a progressive biopharmaceutical company known for tackling some of the toughest cancer types, proudly shares the appointment of Sonal Gupta, M.D., Ph.D., as its Chief Medical Officer (CMO). With a focus on revolutionizing treatment methods, Dr. Gupta's role will be pivotal in implementing advanced strategies that target the steroid receptor coactivator (SRC-3) gene for treating solid tumors.
Insights from Leadership on Dr. Gupta's Appointment
Suneet Varma, CoRegen's Chairman of the Board, expressed enthusiasm about Dr. Gupta joining the team. "As we gear up to migrate our innovative SRC-3 platform into clinical settings, Dr. Gupta's unique blend of clinical development expertise and substantial regulatory experience augments our mission. Her outstanding history in facilitating stages ranging from trial design to global regulatory engagement will be essential for our progress as we evolve into a clinical-stage entity. We are confident that her strategic foresight will help propel our platform towards tangible benefits for patients in need."
Dr. Gupta's Vision and Commitment
Sharing her thoughts, Dr. Gupta remarked, "I am excited to join CoRegen, where the commitment to enhancing patient outcomes intersects with my passion for advancing medical science through collaborative and high-quality research. I am eager to work alongside the team in navigating clinical and regulatory pathways that advance our goals."
Dr. Gupta's Impressive Background
Bringing almost two decades of experience from both biotech and pharmaceutical realms, Dr. Gupta specializes in oncology, gene therapies, and translational medicine. Her previous role as Senior Vice President and Head of Clinical Development at AffyImmune Therapeutics saw her lead efforts in enhancing CAR T-cell therapies, predominantly in studies targeting non-small cell lung cancer and rare tumor types. She has also contributed to the clinical frameworks at AVROBIO, Rubius Therapeutics, CRISPR Therapeutics, and Selecta Biosciences, developing pivotal programs in sickle cell diseases, thalassemia, and solid tumors.
About CoRegen's Innovative Approach to Cancer
CoRegen stands at the forefront of cancer treatment innovation with its groundbreaking focus on the SRC-3 gene in Regulatory T (Treg) cells. This strategic pivot reflects a significant advancement in adoptive cell therapy (ACT), enhancing the immune system's ability to recognize and combat solid tumors. Insights from the O'Malley Lab at Baylor College of Medicine showcase how genetically modified Tregs can alter immune responses and augment the eradication of tumors in preclinical trials.
Understanding Adoptive Cell Therapy (ACT)
Adoptive Cell Therapy (ACT) represents a transformative avenue in immunotherapy. It harnesses the power of either a patient’s own immune cells or those from a donor, which are meticulously collected and modified before being reinfused into the body. This process empowers the immune system in the fight against varied diseases, predominantly cancer.
Exploring the Role of Regulatory T (Treg) Cells in Cancer
Regulatory T (Treg) cells play an indispensable role in maintaining the immune system's integrity by curbing excessive responses and countering autoimmune disorders. Nevertheless, cancer cells can exploit these Tregs to escape immune attacks, leading to persistent tumor growth and metastasis.
Media Contact Information
For further inquiries, please reach out to:
Cammy Duong
LifeSci Communications
cduong@lifescicomms.com
Frequently Asked Questions
What is CoRegen's main focus in cancer treatment?
CoRegen is focused on innovating treatments by targeting the SRC-3 gene within Regulatory T cells to improve the immune response against solid tumors.
Who has CoRegen appointed as Chief Medical Officer?
CoRegen has appointed Dr. Sonal Gupta, a veteran in oncology and clinical development, as the new Chief Medical Officer.
What is the significance of adopting new therapies like ACT?
ACT represents a critical approach to enhance the immune system's capacity to fight cancer through advanced manipulation and reinfusion of immune cells.
How does RegT cells affect cancer progression?
While Treg cells help maintain immune balance, they can also assist cancers in evading immune detection, promoting tumor growth.
How can interested parties learn more about CoRegen?
For detailed information, individuals can follow updates from CoRegen or reach out via media contact.
